In vitro and in vivo evaluation of anti-HER2 antibody conjugates labelled with 225Ac

被引：0
|
作者：
Kateřina Ondrák Fialová [1 ]
Lukáš Ondrák [1 ]
Martin Vlk [1 ]
Ján Kozempel [1 ]
Kateřina Nováková [2 ]
Zbyněk Nový [3 ]
Katarína Hajduová [3 ]
Marián Hajdúch [3 ]
Miloš Petřík [3 ]
Marek Pruszynski [4 ]
Frank Bruchertseifer [5 ]
Alfred Morgenstern [6 ]
机构：
[1] Czech Technical University in Prague,Department of Nuclear Chemistry, Faculty of Nuclear Sciences and Physical Engineering
[2] Institute of Organic Chemistry and Biochemistry of the CAS,European Commission
[3] Institute of Molecular and Translational Medicine,undefined
[4] Faculty of Medicine and Dentistry,undefined
[5] Palacký University,undefined
[6] Institute of Nuclear Chemistry and Technology,undefined
[7] NOMATEN Centre of Excellence,undefined
[8] National Centre for Nuclear Research,undefined
[9] Joint Research Centre,undefined
来源：
EJNMMI Radiopharmacy and Chemistry | / 10卷 / 1期
关键词：
HER2; Pertuzumab; Trastuzumab; Actinium-225; Targeted alpha therapy; SKOV-3; MDA-MB-231;
D O I：
10.1186/s41181-025-00337-8
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [21] Comparative analysis of anti-HER2 antibody-drug conjugates in tumor spheroid models
    McBain, Kirsty
    Barnes, Kalpana
    Bevan, Nicola
    CANCER RESEARCH, 2024, 84 (06)
  • [22] Mechanisms of action and resistance to anti-HER2 antibody-drug conjugates in breast cancer
    Saleh, Khalil
    Khoury, Rita
    Khalife, Nadine
    Chahine, Claude
    Ibrahim, Rebecca
    Tikriti, Zamzam
    Le Cesne, Axel
    CANCER DRUG RESISTANCE, 2024, 7 : 2 - 15
  • [23] Functionalized TiO2 nanoparticles labelled with 225Ac for targeted alpha radionuclide therapy
    Edyta Cędrowska
    Marek Pruszynski
    Agnieszka Majkowska-Pilip
    Sylwia Męczyńska-Wielgosz
    Frank Bruchertseifer
    Alfred Morgenstern
    Aleksander Bilewicz
    Journal of Nanoparticle Research, 2018, 20
  • [24] In vivo evaluation of site-specifically labelled ABD-fused anti-HER2 Affibody molecule for radionuclide therapy
    Orlova, A.
    Ekblad, C.
    Abrahmsen, L.
    Wennborg, A.
    Frejd, F. Y.
    Tolmachev, V.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2009, 36 : S232 - S232
  • [25] RBE, in vivo, for a 212Pb-conjugated anti-HER2/neu antibody
    Liatsou, Ioanna
    Josefsson, Anders
    Cortez, Angel
    Hobbs, Robert F.
    Brayton, Cory
    Torgue, Julien
    Sgouros, George
    CANCER RESEARCH, 2020, 80 (16)
  • [26] A novel anti-HER2 antibody GB235 reverses Trastuzumab resistance in HER2-expressing tumor cells in vitro and in vivo
    Mengjun Shu
    Hongbin Yan
    Chuanying Xu
    Yan Wu
    Zhaohua Chi
    Weihong Nian
    Zhuzi He
    Jing Xiao
    Hongli Wei
    Qing Zhou
    Joe X. Zhou
    Scientific Reports, 10
  • [27] A novel anti-HER2 antibody GB235 reverses Trastuzumab resistance in HER2-expressing tumor cells in vitro and in vivo
    Shu, Mengjun
    Yan, Hongbin
    Xu, Chuanying
    Wu, Yan
    Chi, Zhaohua
    Nian, Weihong
    He, Zhuzi
    Xiao, Jing
    Wei, Hongli
    Zhou, Qing
    Zhou, Joe X.
    SCIENTIFIC REPORTS, 2020, 10 (01)
  • [28] Study of Radioactive Progeny Recoils Release from 225Ac Labelled TiO2 Nanoparticles
    Sakmar, M.
    Kozempel, J.
    Ondrak, L.
    Fialova, K.
    Vlk, M.
    Morgenstern, A.
    Bruchertseifer, F.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2022, 49 (SUPPL 1) : S652 - S652
  • [29] Evaluation of cardiotoxicity by anti-HER2 therapy
    Itagaki, Tomoko
    Kajitani, Keiko
    Ohara, Masahiro
    ANNALS OF ONCOLOGY, 2023, 34 : S1433 - S1434
  • [30] Evaluation of [225Ac]Ac-DOTA-anti-VLA-4 for targeted alpha therapy of metastatic melanoma
    Cortez, Angel
    Josefsson, Anders
    McCarty, Greg
    Shtekler, Abigail E.
    Rao, Akhila
    Austin, Zachery
    Nedrow, Jessie R.
    NUCLEAR MEDICINE AND BIOLOGY, 2020, 88-89 : 62 - 72
12345